Clinical outcome after failure of hypomethylating therapy for myelodysplastic syndrome-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Clinical outcome after failure of hypomethylating therapy for myelodysplastic syndrome

Published:2015-01-07 Issue:6 Volume:94 Page:546-553
ISSN:0902-4441
Container-title:European Journal of Haematology
language:en
Short-container-title:Eur J Haematol

Author:

Lee Je-Hwan¹,Choi Yunsuk¹,Kim Sung-Doo¹,Kim Dae-Young¹,Lee Jung-Hee¹,Lee Kyoo-Hyung¹,Lee Sang-Min²,Lee Won-Sik²,Joo Young-Don³

Affiliation:

1. Department of Hematology; Asan Medical Center; University of Ulsan College of Medicine; Seoul Korea

2. Department of Internal Medicine; Busan Paik Hospital; Inje University College of Medicine; Busan Korea

3. Department of Hematology; Haeundae Paik Hospital; Inje University College of Medicine; Busan Korea

Funder

Korean Health Technology R&D Project, Ministry of Health & Welfare

Publisher

Wiley

Subject

Hematology,General Medicine

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1111/ejh.12469/fullpdf

Reference20 articles.

1. Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III study;Fenaux;Lancet Oncol,2009

2. Decitabine improves patient outcomes in myelodysplastic syndromes: results of a phase III randomized study;Kantarjian;Cancer,2006

3. Poor outcome of patients with myelodysplastic syndrome after azacitidine treatment failure;Duong;Clin Lymphoma Myeloma Leuk,2013

4. Outcome of patients with myelodysplastic syndrome after failure of decitabine therapy;Jabbour;Cancer,2010

5. Outcome of higher-risk myelodysplastic syndrome after azacitidine treatment failure;Prebet;J Clin Oncol,2011

Cited by 12 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Phase 1 study of azacitidine in combination with quizartinib in patients with FLT3 or CBL mutated MDS and MDS/MPN;Leukemia Research;2024-07

2. Phase 1/2 study of CPX‐351 for patients with Int‐2 or high risk International Prognostic Scoring System myelodysplastic syndromes and chronic myelomonocytic leukaemia after failure to hypomethylating agents;British Journal of Haematology;2023-11-10

3. Reciprocal regulation of TWIST1 and OGT determines the decitabine efficacy in MDS/AML;Cell Communication and Signaling;2023-09-22

4. Inhibition of DNMT3B and PI3K/AKT/mTOR and ERK Pathways as a Novel Mechanism of Volasertib on Hypomethylating Agent-Resistant Cells;Biomolecules & Therapeutics;2022-11-16

5. Gene Expression Profiles Identify Biomarkers of Resistance to Decitabine in Myelodysplastic Syndromes;Cells;2021-12-10

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3